LAUSR

Many countries with the highest burdens of cervical cancer have not yet offered HPV vaccines to the majority of their age-eligible girls, who as adults also have limited or no access to effective cervical cancer screening or treatment. There are now two complementary developments that could make HPV vaccines more accessible and affordable: 1) the current and projected increases in HPV vaccine supply and 2) the permissive recommendation for single-dose HPV vaccination schedules. This change in policy paired with the healthier HPV vaccine supply is an incredible opportunity to facilitate rapid access and expansion of HPV vaccination. Female adolescent vaccination including multi-age cohorts must be prioritized. In the coming decades this is the most cost-effective approach to avert millions of projected cervical cancer cases, which account for the majority of HPV-related cancers globally.